Catalent Focus On Expansion And New Technologies At ICSE/CPhI

Catalent To Focus On European Expansion and New Drug Delivery Technologies at ICSE/CPhI Worldwide 2011

Somerset, NJ – October 20, 2011 – With the pending acquisition of Aptuit’s clinical trials business, investment in OptiMelt™ hot melt technology, and expansion of its facilities in Aprilia, Italy, Swindon, UK and Schorndorf, Germany, Catalent Pharma Solutions will focus on expansion of its technologies and capabilities at ICSE / CPhI Worldwide in Frankfurt, Germany on October 25-27.

Catalent will highlight several new drug development and delivery options, including alliances with Sanwa Pharmaceuticals and Pantec AG for the global launch of OSDrC® OptiDose™ flexible modified release delivery, and Lyopan® fast-dissolve technology, respectively.

The pending addition of Aptuit’s clinical trials supplies and pharmaceutical development and manufacturing operations will make Catalent a global leader in clinical trial solutions and further enhances its #1 position as a drug development and formulation partner globally. 

On Tuesday, October 25, Catalent will host a Cocktail Reception on their stand (#40F04) from 1500-1600 hours to celebrate all their growth initiatives.
Additionally, Catalent experts will present on:

  • Monday, October 24, Will Downie, Senior Vice President of Global Sales & Marketing, will participate on the panel of CPhI’s “Contract Partnership Executive Summit.”  Panel discussions will center on the future of the pharma outsourcing industry.  The panel will consider production costs, regulatory standards and convergence across international borders.  More information on the summit may be found at .
  • Wednesday, October 26, Edwin Hoppenbrouwer, Catalent’s Director of New Product Introduction, will present at the Speakers Corner of the Innopack exhibition on the subject of “Solving Tech Transfer Challenges for Complex Pharmaceutical Products."

On Wednesday evening, the nearby Frankfurt Marriott Hotel will play host to the 6th Anniversary of the European Outsourcing Awards.  Catalent is a finalist in two categories for the “Most Effective Scale-Up/Tech Transfer” and “Outsourcing Executive of the Year.”

To schedule an interview with Catalent during CPhI Worldwide 2011, please contact Patricia McGee or Chris Halling at .

For more information on Catalent at ICSE, visit .

About Catalent

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs more than 8,000 people at 20+ facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ.

more products. better treatments. reliably supplied.™

OSDrC is a registered trademark of Sanwa Kagaku Kenkyusho Co., Ltd
Lyopan is a registered trademark of Pantec AG